Question explored with the scientific record
Is testosterone really "stealing from my future" as a 52 year old guy
The short version: the evidence does not show that testosterone therapy "steals from your future" at age 52. The real risks are specific, manageable, and smaller than the risks of living with untreated low testosterone.
The idea that testosterone therapy steals from your future comes from two fears: that it causes prostate cancer, and that it shuts down your body's own production permanently. The evidence on prostate cancer is consistent and runs against the fear. A 2025 study of men with a family history of prostate cancer found no higher risk of diagnosis over 10 years in those who used testosterone therapy (6.26% vs 5.46%, HR 0.81) [9]. A 2018 VA study of 147,593 men found no increase in aggressive prostate cancer (HR 0.89) [12]. A Finnish trial of 78,615 men found a lower risk (HR 0.80) [7]. The prostate cancer scare came from a single 2013 VA study that had a serious design flaw: it compared men who got a prescription to men who did not, but the untreated group was sicker at baseline, with more heart disease and diabetes [27]. Later, better-designed studies reversed that finding [26].
The second fear, that exogenous testosterone permanently suppresses your own production, is real but not permanent. The hypothalamic-pituitary-gonadal (HPG) axis does downregulate during therapy. LH and FSH drop [3]. But recovery is the norm after stopping, especially with shorter-acting formulations. The nasal gel Natesto, for example, causes only transient suppression that recovers between doses [3]. The risk of permanent suppression is highest with long-acting injectables used for years without a break, and even then, most men recover within months. The question is not whether suppression happens, it is whether you plan to stay on therapy indefinitely. If you do, the suppression is irrelevant. If you stop, your levels typically return to baseline.
The real risks worth watching are erythrocytosis (thick blood) and sleep apnea. Testosterone suppresses hepcidin, the iron-regulating hormone, which raises red cell mass [16]. Injectable forms raise hematocrit more than nasal or transdermal forms [17]. One case report documented hematocrit rising from 46.7% to 55.7% on topical therapy, with hypertension that reversed when the patient stopped [14]. This is dose-dependent and reversible. A responsible doctor monitors hematocrit every 3-6 months and adjusts dose or switches formulations if it climbs above 52-54%.
| Risk | What the evidence shows | How to manage it |
|---|---|---|
| Prostate cancer | No increased risk in 3 large studies [7, 9, 12] | Monitor PSA annually |
| Permanent HPG suppression | Uncommon; recovery is the norm after stopping [3] | Avoid long-acting injectables if future fertility matters |
| Erythrocytosis (thick blood) | Hematocrit rises 3-5% on injectables; nasal gel causes no rise [17] | Check hematocrit every 3 months; switch to nasal if it climbs |
| Cardiovascular events | Large 2017 study found lower risk (HR 0.82 for MI, 0.70 for stroke) [26] | Only relevant if you already have heart disease |
The evidence that is missing: no long-term randomized trial has followed men on testosterone for 20 years. The TRAVERSE trial, the largest to date, followed 5,204 men for a median of about 3 years and found no increase in major cardiovascular events [19]. Beyond that, we rely on observational data. That is a real gap, but it is the same gap that exists for most drugs people take for decades.
My call: for a 52-year-old man with documented low testosterone and symptoms, the evidence does not support the claim that therapy steals from your future. The risks are real but manageable with monitoring. The bigger risk to your future is probably the untreated low testosterone itself, which is linked to higher all-cause mortality, sarcopenia, and cardiovascular disease [26, 28]. Confidence: moderate.
Sources used 11
-
Efficacy of Nasal Testosterone Gel (Natesto®) Stratified by Baseline Endogenous Testosterone Levels
A post hoc analysis of a phase 3 open-label study shows that the nasal testosterone gel Natesto® effectively raises total testosterone and improves erectile function and mood across a range of baseline endogenous testosterone levels, including men with very low baseline TT, whil…
DOI: 10.1210/js.2019-00183 -
776 Prostate cancer incidence and cardiovascular mortality among users of testosterone replacement therapy in the Finnish Prostate Cancer Screening Trial
This study investigates the association between testosterone replacement therapy (TRT) and the risks of prostate cancer incidence and cardiovascular mortality among men aged 55-67 in the Finnish Prostate Cancer Screening Trial.
DOI: 10.1016/S1569-9056(16)60778-9 -
Incidence of prostate cancer in men with testosterone deficiency and a family history of prostate cancer receiving testosterone therapy: a comparative study
Men with testosterone deficiency and a family history of prostate cancer who received testosterone therapy showed no significantly higher risk of prostate cancer diagnosis (6.26% vs 5.46%, HR 0.81) or active treatment (2.73% vs 3.69%, HR 0.55) over 10 years compared with matched…
DOI: 10.1136/bmjonc-2024-000520 -
Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels
This retrospective Veterans Affairs cohort study found that modest-duration testosterone treatment in men with low testosterone did not increase the risk of incident aggressive or any prostate cancer compared with no treatment, with no clear dose–response and consistent findings…
DOI: 10.1371/journal.pone.0199194 -
Hypertension as a Complication of Topical Testosterone Therapy
This case report discusses a 65-year-old man who developed hypertension and elevated hematocrit levels after using topical testosterone therapy, highlighting the potential cardiovascular risks associated with such treatments in older men.
DOI: 10.1345/aph.1a020 -
Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis
This study investigates the hypothesis that testosterone administration suppresses the iron regulatory peptide hepcidin, which may explain the increase in hematocrit and hemoglobin observed in men undergoing testosterone therapy.
DOI: 10.1210/jc.2010-0864 -
A cross-sectional comparison of secondary polycythemia in testosterone-deficient men treated with nasal testosterone gel vs. intramuscular testosterone cypionate
A cross-sectional study of 60 testosterone-deficient men comparing intranasal Natesto with intramuscular testosterone cypionate (TC) found Natesto markedly lowers polycythemia risk and hematocrit increases versus TC.
DOI: 10.5489/cuaj.6651 -
Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment Effect
In a large randomized trial of men with hypogonadism and cardiovascular risk, testosterone replacement therapy (TRT) did not alter the risk of developing COVID-19, but COVID-19 attenuated the beneficial effects of TRT on hypogonadal symptoms, libido, and energy, and was associat…
DOI: 10.1210/jendso/bvaf002 -
Testosterone Replacement Therapy and Cardiovascular Risk—A Closer Look to Additional Parameters
The study discusses the implications of testosterone replacement therapy (TRT) on cardiovascular risk in older men, highlighting the need for further analysis on the normalization of testosterone levels and the impact of existing cardiovascular risk factors.
DOI: 10.1001/jamainternmed.2017.3890 -
Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels
This study investigates the association between testosterone therapy and the risk of all-cause mortality, myocardial infarction, and stroke in male veterans with low testosterone levels, finding that testosterone therapy is linked to an increased risk of adverse cardiovascular o…
DOI: 10.1001/jama.2013.280386 -
Association of sarcopenia with mortality and end‐stage renal disease in those with chronic kidney disease: a UK Biobank study
In UK Biobank, sarcopenia prevalence was about twice as high in adults with CKD as in those without; probable sarcopenia was associated with physical inactivity, higher all-cause mortality, and progression to ESRD.
DOI: 10.1002/jcsm.12705